Wave Life Sciences, Inc.
WVE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001631574
In the last 90 days, Wave Life Sciences, Inc. insiders filed 0 open-market purchases and 4 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
13F holders, Q4 2023
Institutional positions in Wave Life Sciences, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- +30 vs. Q3 2023
- Shares held
- 92.5M
- +19.9M (+27.5%) vs. Q3 2023
- Total value
- $468.0M
- +$50.6M (+12.1%) vs. Q3 2023
- New holders
- 40
- 48 more added
- Sold out
- 10
- 11 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting WVE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 239 | $1.06B |
| Q1 2026 | 232 | $1.25B |
| Q4 2025 | 219 | $3.11B |
| Q3 2025 | 189 | $1.05B |
| Q2 2025 | 177 | $903.1M |
| Q1 2025 | 197 | $1.06B |
| Q4 2024 | 184 | $1.59B |
| Q3 2024 | 162 | $986.1M |
| Q2 2024 | 144 | $474.4M |
| Q1 2024 | 132 | $572.3M |
| Q4 2023 | 115 | $468.0M |
| Q3 2023 | 85 | $417.4M |
| Q2 2023 | 81 | $262.7M |
| Q1 2023 | 73 | $303.5M |
| Q4 2022 | 75 | $476.9M |
| Q3 2022 | 61 | $242.8M |
| Q2 2022 | 60 | $220.3M |
| Q1 2022 | 82 | $95.4M |
| Q4 2021 | 90 | $148.5M |
| Q3 2021 | 88 | $183.5M |
| Q2 2021 | 87 | $246.7M |
| Q1 2021 | 102 | $214.8M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Wave Life Sciences, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 1,459,764 | $7.37M | 0.00% | +64,627+4.6% | Added |
| Takeda Pharmaceutical Co Ltd | 1,346,892 | $7.57M | 2.31% | +1,346,892 | New |
| Price T Rowe Associates Inc | 1,627,363 | $8.22M | 0.00% | +358,201+28.2% | Added |
| Citadel Advisors LLC | 1,982,252 | $10.0M | 0.01% | +1,982,252 | New |
| Artal Group S.A. | 3,007,400 | $15.2M | 0.52% | +1,007,400+50.4% | Added |
| Point72 Asset Management, L.P. | 3,213,500 | $16.2M | 0.05% | +3,213,500 | New |
| Primecap Management Co | 3,759,408 | $19.0M | 0.02% | −21,100−0.6% | Reduced |
| Kynam Capital Management, LP | 3,932,082 | $19.9M | 2.25% | 00.0% | Unchanged |
| Bellevue Group AG | 4,494,458 | $22.7M | 0.35% | 00.0% | Unchanged |
| BlackRock Inc. | 5,366,288 | $27.1M | 0.00% | +502,522+10.3% | Added |
| 683 Capital Management, LLC | 5,600,000 | $28.3M | 2.83% | −250,000−4.3% | Reduced |
| Adage Capital Partners GP, L.L.C. | 5,987,730 | $30.2M | 0.06% | +2,200,000+58.1% | Added |
| M28 Capital Management LP | 7,373,413 | $37.2M | 30.85% | +328,913+4.7% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 8,447,804 | $42.7M | 0.88% | +1,853,485+28.1% | Added |
| Ra Capital Management, L.P. | 18,202,009 | $91.9M | 1.44% | +1,000,000+5.8% | Added |
| XTX Topco Ltd | 0 | $0 | 0.00% | −32,280−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −23,545−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −19,657−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −17,119−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −16,811−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −15,910−100.0% | Sold out |
| Clear Harbor Asset Management, LLC | 0 | $0 | 0.00% | −14,000−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −4,003−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −2,350−100.0% | Sold out |
| TD Waterhouse Canada Inc. | 0 | $0 | 0.00% | −400−100.0% | Sold out |